Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 5/20 | 0.44 |
| ▸ | FNTB | P49356 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.43 |
| ▸ | CTSD | P07339 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288030 | 0.96 | ACE (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL30288010 | 0.96 | ACE (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL29714707 | 0.93 | MME (0.44) | ACEFNTAFNTBMAPTBACE1 | |
| SCHEMBL21828595 | 0.91 | ACE (0.61) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL21828594 | 0.91 | ACE (0.61) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL30011243 | 0.91 | FNTA (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL30010590 | 0.91 | FNTA (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL30010811 | 0.91 | FNTA (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL30011210 | 0.91 | FNTA (0.48) | ACEFNTAFNTBBACE1CTSD | |
| SCHEMBL30011232 | 0.91 | FNTA (0.48) | ACEFNTAFNTBBACE1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | disclosed |
| CN-109475640-B | Mixed carrier for nucleic acid carried article | 库瑞瓦格欧洲公司 | 2023-03-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ACE 3951/4885FNTA 2788/4885FNTB 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.